Venetoclax Falls Short in 15 Month MDS Survival Challenge but Hope Remains

Venetoclax, approved by the FDA in 2016 for treating 17p-deleted chronic lymphocytic leukemia (CLL), has been a blockbuster drug in hematologic cancers, earning over $2 billion in sales in 2024. Despite its success in acute myeloid leukemia (AML), AbbVie’s ambitions to expand Venetoclax into the myelodysplastic syndrome (MDS) market have faced significant setbacks.

MDS, a hematologic malignancy with an average survival of only 15 months and a 5-year survival rate below 20%, presents major challenges for drug development due to heterogeneous disease profiles and the lack of effective models. Current standard treatments, such as hypomethylating agents (HMAs) like azacitidine and decitabine, often result in drug resistance, leaving more than 50% of patients without alternatives.

Venetoclax, a BCL-2 inhibitor, offers a chemo-free approach by inducing mitochondrial apoptosis. Encouraged by its success in AML, AbbVie initiated clinical trials targeting MDS. In a Phase 1b trial involving 107 patients, Venetoclax combined with azacitidine showed promising response rates, with 29.9% achieving complete remission (CR) and a median overall survival (OS) of 26 months. However, all patients experienced adverse events, raising concerns about its safety.

The drug’s Phase 3 trial, critical for regulatory approval, failed to demonstrate a significant survival benefit for MDS patients. Experts attribute this to MDS's greater reliance on MCL-1 rather than BCL-2, making Venetoclax less effective in this population. Additionally, TP53 mutations, present in up to 90% of MDS patients, further limit efficacy by disrupting DNA repair pathways.

Beyond efficacy, Venetoclax’s toxicity profile poses challenges. Its apoptosis-inducing effects harm healthy bone marrow cells, exacerbating anemia and neutropenia in MDS patients, who are already vulnerable to life-threatening infections.

Despite this setback, the unmet clinical need in MDS remains significant. Other BCL-2 inhibitors, including Ascentage Pharma’s APG-2575, are showing promising Phase 1 results, with ORR reaching 75% in relapsed/refractory MDS patients. The race to capture the MDS market, estimated in billions of dollars, is far from over.